Patents Represented by Attorney Gregory J. Giotta
-
Patent number: 5846945Abstract: Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.Type: GrantFiled: June 7, 1995Date of Patent: December 8, 1998Assignee: ONYX Pharmaceuticals, Inc.Inventor: Francis McCormick
-
Patent number: 5801029Abstract: Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.Type: GrantFiled: June 7, 1995Date of Patent: September 1, 1998Assignee: Onyx Pharmaceuticals, Inc.Inventor: Francis McCormick
-
Patent number: 5756669Abstract: The invention provides mammalian polypeptides which bind wild-type and/or mutant mamalian p53 proteins, polynucleotides encoding such polypeptides, screening assays for drug development employing such polypeptides and polynucleotides, immunological and other reagents for diagnostic, therapeutic, and research applications.Type: GrantFiled: March 2, 1995Date of Patent: May 26, 1998Assignee: Onyx Pharmaceuticals, Inc.Inventors: James R. Bischoff, Lelia Wu
-
Patent number: 5698428Abstract: A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity.Type: GrantFiled: January 10, 1997Date of Patent: December 16, 1997Assignee: Onyx Pharmaceuticals, Inc.Inventors: Arie Abo, George A. Martin
-
Patent number: 5470842Abstract: Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation.Type: GrantFiled: March 2, 1992Date of Patent: November 28, 1995Assignee: Glycomed, IncorporatedInventors: Brian K. Brandley, Michael Tiemeyer, Stuart J. Swiedler, Margaret Moreland, Hans Schweingruber
-
Patent number: 5440015Abstract: Peptides are described and methods of using the peptides to treat or prevent disease which peptides are described by the formula:SEQ. ID NO:1wherein X is an aromatic amino acid, and n is 1, 2, or 3; X' is either a non-polar or polar uncharged amino acid, and n' is 1, 2, or 3; X" is a basic amino acid, and n" is 1 or 2.Type: GrantFiled: March 29, 1993Date of Patent: August 8, 1995Assignee: Glycomed IncorporatedInventors: Bruce A. Macher, John B. Briggs
-
Patent number: 5428025Abstract: Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation. The ligands are encompassed by general structural formula I as follows: ##STR1## wherein one of F and G is hydrogen and one is an N-acetyl neuraminic acid residue on the terminal unit and are both hydrogen on any other unit; J is hydrogen, a lactosylceramide or a linking group and K is hydrogen or a fucose residue and n is an integer of from 1 to 10 (preferably 3 or 4) with the proviso that n and K are defined such that at least one K is a fucose residue.Type: GrantFiled: March 2, 1992Date of Patent: June 27, 1995Assignee: Glycomed IncorporatedInventors: Brian K. Brandley, Michael Tiemeyer, Stuart J. Swiedler, Margaret Moreland, Hans Schweingruber
-
Patent number: 5412123Abstract: Derivatives of anthraquinone and anthracene are synthesized and formulated into pharmaceutical formulations. When the formulations are administered the derivatives act as ligands binding to an interrupting the biological chain of events associated with selectin receptors in the human body.Type: GrantFiled: February 8, 1993Date of Patent: May 2, 1995Assignee: Glycomed IncorporatedInventors: Narasinga Rao, Peng C. Tang, John H. Musser
-
Patent number: 5326752Abstract: The compounds are of the formula ##STR1## wherein each R.sup.1 is independently H or lower alkyl (1-4C); R.sup.2 is H, lower alkyl (1-4C), alkylaryl or one or more additional saccharide residues; R.sup.3 and R.sup.4 are independently H, alkyl (1-6C), aryl or R.sup.3 and R.sup.4, taken together, form a five or six-membered ring optionally containing a hetroatom selected from the group consisting of O, S, and NR.sup.1 ; wherein said five- or six-membered ring may further be substituted by one or more substituents selected from the group consisting of (CHOR.sup.1).sup.m H wherein m is 1-4, OR.sup.1, OOCR.sub.1, NR.sup.1, NCOR.sup.1 and SR.sup.1 ; Y is H, OR.sup.1, OOCR.sup.1, NR.sup.1.sub.2, NCOR.sub.1 or SR.sub.1 ; and X is --CHR.sup.5 (CHOR.sup.1).sub.2 CHR.sup.6 OR.sup.1 wherein R.sup.5 and R.sup.6 are independently H, lower alkyl (1-4C) optionally substituted with one or more R, or result in a five- or six-membered ring optionally containing a heteroatom selected from the group consisting of O, S and NR.sup.Type: GrantFiled: November 27, 1991Date of Patent: July 5, 1994Assignee: Glycomed IncorporatedInventors: Mina Nashed, Falguni Asgupta, Saeed Abbas, John Musser, Darwin Asa
-
Patent number: 5296471Abstract: Methods of making and using, as prophylatics or therapeutics for preventing or treating certain diseases including cancer, O-desulfated heparin compositions, preferably 2-O, 3-O desulfated heparin compositions, wherein the methods permit regulating the degree of 2-O, 3-O desulfation to produce compositions that are variably desulfated including about 99% and 75% desulfated at the 2-O and 3-O positions, respectively.Type: GrantFiled: December 22, 1992Date of Patent: March 22, 1994Assignee: Glycomed IncorporatedInventors: Kevin R. Holme, Patrick N. Shaklee, David J. Tyrrell
-
Patent number: 5280016Abstract: A non-anticoagulant (NAC) form of heparin which shows antiproliferative activity with respect to smooth muscle cells is useful in the prevention of restenosis and other conditions benefited by antiproliferative activity with respect to smooth muscle cells. This NAC form of heparin is prepared by oxidizing heparin/heparan sulfate to a desired level with periodate followed by reduction of the resulting aldehyde groups; all under conditions which prevent depolymerization of the heparin.Type: GrantFiled: September 3, 1991Date of Patent: January 18, 1994Assignee: Glycomed IncorporatedInventors: H. Edward Conrad, Yuchuan Guo
-
Patent number: 5268384Abstract: Synthetic mammalian matrix metalloprotease inhibitors are useful in controlling angiogenesis. These compounds are thus useful in controlling the growth of tumors and in controlling neovascular glaucomas.Type: GrantFiled: January 7, 1992Date of Patent: December 7, 1993Inventor: Richard E. Galardy
-
Patent number: 5252603Abstract: Succinylacetone derived or related medicaments and methods of synthesis of the same are shown wherein the medicaments consists of succinylacetonyl-proline-PEG, succinylacetonyl-NH-PEG, or compounds that have the formula: ##STR1## wherein n=1-6R=CH.sub.3, CF.sub.3, --CO.sub.2 R.sup.IV, ##STR2## R.sup.I, R.sup.II =H, F, CH.sub.3, or ##STR3## R.sup.III =H, ##STR4## or tetrazolyl R.sup.IV =H, or alkyland that have immunosuppressive activity both in vivo and in vitro based on their activities in cellular immunologic assays and adjuvant induced arthritis in rats, respectively.Type: GrantFiled: December 6, 1990Date of Patent: October 12, 1993Assignee: Cetus CorporationInventors: Danute E. Nitecki, Lois Aldwin, Corey H. Levenson, Margaret Moreland, Irwin Braude, David F. Mark, Henry Rapoport
-
Patent number: 5250519Abstract: A non-anticoagulant (NAC) form of heparin which shows antiproliferative activity with respect to smooth muscle cells is useful in the prevention of restenosis and other conditions benefited by antiproliferative activity with respect to smooth muscle cells. This NAC form of heparin is prepared by deacetylating and then oxidizing heparin/heparan sulfate substantially to completion with periodate followed by reduction of the resulting aldehyde groups under conditions which prevent depolymerization of the heparin.Type: GrantFiled: March 29, 1991Date of Patent: October 5, 1993Assignee: Glycomed IncorporatedInventors: H. Edward Conrad, Yuchuan Guo
-
Patent number: 5239078Abstract: Compounds of the formulas ##STR1## wherein each R.sup.1 is independently H or alkyl (1-8C) and R.sup.2 is alkyl (1-8C) or wherein the proximal R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.p -- wherein p=3-5;R.sup.3 is H or alkyl (1-4C);R.sup.4 is fused or conjugated unsubstituted or substituted bicycloaryl methylene;n is 0, 1 or 2;m is 0 or 1; andx is OR.sup.5 or NHR.sup.5, wherein R.sup.5 is H or substituted or unsubstituted alkyl (1-12C), aryl (6-12C), aryl alkyl (6-16C); orX is an amino acid residue or amide thereof; orX is the residue of a cyclic amine or heterocyclic amine;Y is selected from the group consisting of R.sup.7 ONR.sup.6 CONR.sup.6 -, R.sup.6.sub.2 NCONOR.sup.7 -, and R.sup.6 CONOR.sup.7 -, wherein each R.sup.6 is independently H or lower alkyl (1-4C); R.sup.7 is lower alkyl (1-4C) or an acyl group; andwherein --CONR.sup.3 -- is optionally in modified isoteric form are inhibitors of matrix metalloproteases.Type: GrantFiled: August 20, 1991Date of Patent: August 24, 1993Assignee: Glycomed IncorporatedInventors: Richard E. Galardy, Damian Grobelny, John H. Musser
-
Patent number: 5234839Abstract: Compositions useful for detecting ras gene proteins are described consisting of GTP and a protein having an apparent reduced molecular weight of about 115,000-120,000 daltons, or fragments derived therefrom, that stimulate ras protein guanosine triphosphatase activity. Also described are methods whereby the compositions are used to identify cancer therapeutics.Type: GrantFiled: March 20, 1991Date of Patent: August 10, 1993Assignee: Cetus Oncology CorporationInventors: Frank P. McCormick, Kirston E. Koths, Robert F. Halenbeck, Mary M. Trahey
-
Patent number: 5216005Abstract: Succinylacetone derived or related medicaments and methods of synthesis of the same are shown wherein the medicaments consists of succinylacetonyl-proline-PEG, succinylacetonyl-NH-PEG, or compounds that have the formula: ##STR1## and that have immunosuppressive activity both in vivo and in vitro based on their activities in cellular immunologic assays and adjuvant induced arthritis in rats, respectively.Type: GrantFiled: December 6, 1990Date of Patent: June 1, 1993Assignee: Cetus CorporationInventors: Danute E. Nitecki, Lois Aldwin, Corey H. Levenson, Margaret Moreland, Irwin Braude, David F. Mark, Henry Rapoport
-
Patent number: 5211937Abstract: Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation.Type: GrantFiled: April 11, 1991Date of Patent: May 18, 1993Assignee: Glycomed IncorporatedInventors: Brian K. Brandley, Michael Tiemeyer, Stuart J. Swiedler, Margaret Moreland, Hans Schweingruber
-
Patent number: 5211936Abstract: Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation. The ligands are encompassed by general structural formula I as follows: ##STR1## wherein one of F and G is hydrogen and one is an N-acetyl neuraminic acid residue on the terminal unit and are both hydrogen on any other unit; J is hydrogen, a lactosylceramide or a linking group and K is hydrogen or a fucose residue and n is an integer of from 1 to 10 (preferably 3 or 4) with the proviso that n and K are defined such that at least one K is a fucose residue.Type: GrantFiled: July 30, 1990Date of Patent: May 18, 1993Assignee: Glycomed IncorporatedInventors: Brian K. Brandley, Michael Tiemeyer, Stuart J. Swiedler, Margaret Moreland, Hans Schweingruber
-
Patent number: 5189178Abstract: Compounds of the formulas ##STR1## wherein each R.sup.1 is independently H or alkyl (1-8C) and R.sup.2 is alkyl (1-8C) or wherein the proximal R.sup.1 and R.sup.2 taken together are --(CH.sub.2).sub.p -- wherein p=3-5;R.sup.3 is H or alkyl (1-4C);R.sup.4 is fused or conjugated unsubstituted or substituted bicycloaryl methylene;n is 0, 1 or 2;m is 0 or 1; andX is OR.sup.5 or NHR.sup.5, wherein R.sup.5 is H or substituted or unsubstituted alkyl (1-12C), aryl (6-12C), aryl alkyl (6-16C); orX is an amino acid residue or amide thereof; orX is the residue of a cyclic amine or heterocyclic amine;wherein R.sup.6 is H or lower alkyl (1-4C) and R.sup.7 is H, lower alkyl (1-4C) or an acyl group, and wherein --CONR.sup.3 -- is optionally in modified isosteric formare useful for treating conditions which are characterized by unwanted matrix metalloprotease activities.Type: GrantFiled: August 20, 1991Date of Patent: February 23, 1993Inventors: Richard E. Galardy, Damian Grobelny